Notable 52-Week Highs and Lows of the Day 02/25: (HTZ) (AMGN) (UAL) High; (AFFY) (DVAX) (CLSN) Low

February 25, 2013 1:52 PM EST Send to a Friend
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:
  • Hertz Global Holdings (NYSE: HTZ) $20.35. Hertz higher after reporting Q4 results earlier. EPS of 33 cents and revs of $2.3 billion topped expectations calling for EPS of 31 cents and revs of $2.24 billion. For an updated outlook, click here.

  • Amgen Inc. (Nasdaq: AMGN) high of $91.25. Amgen issued comments an analysis by the Congressional Budget Office released this week. The company said that, contrary to the implications of past media reports, keeping oral-only drugs in Medicare Part D would actually achieve significant savings over time for both taxpayers and the Medicare program.

  • United Continental Holdings, Inc. (NYSE: UAL) high of $27.22. United Continental moving higher on analyst comments that consumer might be more open to rate hikes now than previously in 2013.

  • Gilead (Nasdaq: GILD) high of $43.35. Gilead boosted a little today as Bank of America/Merrill Lynch added the stock to its US 1 List. Shares were up as much as 2.1 percent on Monday's session.
52-Week Low:
  • Affymax, Inc. (Nasdaq: AFFY) low of $2.34. Affymax and Takeda Pharmaceutical Company Limited announced that they have decided to voluntarily recall all lots of OMONTYS Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal. Shares fell 85.8 percent to the new low today. Analysts have largely taken the knife to Affymax, click here for more color.

  • Dynavax Technologies Corp. (Nasdaq: DVAX) low of $1.87. Dynavax reported that it received a Complete Response Letter (CRL) from the FDA regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine.

  • Frontline (NYSE: FRO) low of $2.10. Frontline still moving lower after reporting a narrower-than-expected Q4 loss of 21 cents per share last Friday, though guidance left something to be desired. For more color, click here.

  • Celsion Corp (Nasdaq: CLSN) low of $1.02. Investors still pricing in a $15 million at-the-market registered direct offering, which was announced last week.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Merrill Lynch, Bank of America, Earnings

Add Your Comment